REVIEW

Haemolytic uremic syndrome: diagnosis and management

[version 1; peer review: 3 approved]

Neil S. Sheerin , Emily Glover

National Renal Complement Therapeutics Centre, Institute of Cellular Medicine, Newcastle University and Biomedical Research Centre, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle-upon-Tyne, UK

V1 First published: 25 Sep 2019, 8(F1000 Faculty Rev):1690
<https://doi.org/10.12688/f1000research.19957.1>

Latest published: 25 Sep 2019, 8(F1000 Faculty Rev):1690
<https://doi.org/10.12688/f1000research.19957.1>

Abstract

The thrombotic microangiopathies (TMAs) are a group of diseases characterised by microangiopathic haemolysis, thrombocytopenia, and thrombus formation leading to tissue injury. Traditionally, TMAs have been classified as either thrombotic thrombocytopenic purpura (TTP) or haemolytic uremic syndrome (HUS) based on the clinical presentation, with neurological involvement predominating in the former and acute kidney injury in the latter. However, as our understanding of the pathogenesis of these conditions has increased, it has become clear that this is an over-simplification; there is significant overlap in the clinical presentation of TTP and HUS, there are different forms of HUS, and TMAs can occur in other, diverse clinical scenarios. This review will discuss recent developments in the diagnosis of HUS, focusing on the different forms of HUS and how to diagnose and manage these potentially life-threatening diseases.

Keywords

Haemolytic Uraemic Syndrome, Thrombotic microangiopathy, Complement

Open Peer Review

Approval Status

	1	2	3
version 1 25 Sep 2019

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Chantal Loirat**, Assistance Publique-Hôpitaux de Paris, Paris, France
2. **Richard Coward**, University of Bristol, Bristol, UK
3. **Aoife Waters**, Great Ormond Street Institute of Child Health, London, UK

Any comments on the article can be found at the end of the article.

Corresponding author: Neil S. Sheerin (neil.sheerin@ncl.ac.uk)

Author roles: Sheerin NS: Writing – Original Draft Preparation; Glover E: Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Neil Sheerin has received sponsorship to attend meetings from Alexion Pharmaceuticals. Emily Glover declares that she has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Sheerin NS and Glover E. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Sheerin NS and Glover E. **Haemolytic uremic syndrome: diagnosis and management [version 1; peer review: 3 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1690 <https://doi.org/10.12688/f1000research.19957.1>

First published: 25 Sep 2019, 8(F1000 Faculty Rev):1690 <https://doi.org/10.12688/f1000research.19957.1>

Introduction

The term thrombotic microangiopathy (TMA) refers to a group of diseases characterised by endothelial dysfunction and the formation of platelet- and fibrin-rich thrombi in small blood vessels. As the thrombus forms, there is consumption of platelets and mechanical disruption of erythrocytes, which leads to the typical haematological manifestations of TMA, thrombocytopenia and microangiopathic haemolytic anaemia (schistocyte [fragment] formation, raised lactate dehydrogenase, and reduced haptoglobin). Previously, the TMAs were classified according to their clinical presentation with neurological symptoms predominating in thrombotic thrombocytopenic purpura (TTP) and acute kidney injury (AKI) in haemolytic uremic syndrome (HUS). However, there is significant overlap in the clinical features of TTP and HUS and the diseases are now classified based on aetiology. TTP is caused by an inherited or acquired (inhibitory autoantibody) defect in ADAMTS13 activity, a circulating protease responsible for the degradation of ultra-large von Willebrand factor multimers. In the absence of ADAMTS13, these multimers accumulate on the surface of endothelial cells, leading to the formation of platelet-rich thrombi.

The classification of HUS is more complex, as a pattern of clinical disease consistent with HUS can occur in a wide range of clinical scenarios. Most cases (90%) occur following infection with a Shiga toxin-producing bacteria, either enterohaemorrhagic *Escherichia coli* (STEC) or *Shigella dysenteriae*, and typically affect children. The remaining 10% of cases have traditionally been grouped together as atypical HUS. However, as our understanding of the pathogenesis of HUS has increased over the last 20 years, it has become clear that atypical HUS is not one but many different diseases with similar clinical features. A TMA with a pattern of disease consistent with HUS can occur because of inherited disorders, acquired disease states (including malignancy and autoimmune disease), in pregnancy, in severe hypertension, and in response to drugs. The situation is further complicated by the interaction between inherited predisposition to disease and environmental triggers. As a consequence, there is still no universally accepted classification of HUS. In this review, we will, as far as possible, classify HUS according to its aetiology but accept that this may not capture the complexity of the disease pathogenesis.

HUS associated with infection

Infections are the most common cause of HUS. In addition, infection, for example influenza¹, may act indirectly as a trigger for the development of a TMA in patients with a genetic predisposition to disease.

Shiga toxin-induced HUS

HUS associated with infection with a Shiga toxin-producing bacteria (usually STEC HUS) is one of the commonest causes of AKI in children but can occur at any age². Although adaptive immune responses can be identified after exposure to enteropathogenic *E. coli*, it is unclear whether these are protective³, and the higher rate of infection in children may be due to more frequent exposure. The annual incidence of STEC HUS is approximately 0.7 cases per 100,000 population, with the highest incidence in the summer months. In Europe and North

America, *E. coli* O157 is the serotype most commonly associated with HUS; however, this appears to be changing, with fewer cases of O157-associated HUS and increasing numbers of cases due to other serotypes reported in some countries⁴. In parts of Asia, *S. dysenteriae* type 1 infection is the most common precipitant.

Clinical features. Abdominal pain, diarrhoea (bloody in 60%), and vomiting typically occur 3 days after ingestion of bacteria. Approximately 10% of patients exposed to bacteria will then develop HUS. The development of HUS is influenced by both pathogen- (inoculum size, pathogen strain, and type of toxin produced) and host-related factors (microbiome⁵, antimotility and antibiotic drug use, inflammatory response, and possible genetic factors⁶). In 5–10% of patients with STEC HUS, there will be no preceding history of diarrhoea, highlighting the importance of microbiological investigation of all patients with a TMA irrespective of history⁷.

Renal involvement is present in most cases and dialysis is required in 50%. Renal recovery after 1–2 weeks is usual, and end-stage renal disease (ESRD) after the initial presentation is uncommon. Neurological involvement is the most frequently reported extra-renal manifestation with seizures and reduced consciousness levels reported in up to one-third of cases^{8,9}. Other sites that can be affected include the intestinal tract and pancreas, eyes, and heart. The mortality rate in the acute phase of the disease is approximately 2–5%¹⁰ in STEC HUS but is higher when HUS follows *Shigella* infection¹¹. Long-term renal sequelae are common, with hypertension and chronic kidney disease (CKD) occurring in 25–40% of patients^{12,13}.

Pathogenesis. Shiga toxin-producing *E. coli* can colonise the intestine of healthy animals and can enter the food chain if infected meat or other food products are consumed. Pathogenic *E. coli* closely associate with the gastrointestinal mucosa and toxin translocates through the epithelium into the circulation where it binds to circulating erythrocytes and leukocytes. The toxin, which comprises one A and five B subunits, binds to globotriaosylceramide (Gb3) on the surface of target cells. It is taken up by endocytosis and is then retrogradely transported to the endoplasmic reticulum¹⁴. The A subunit inhibits protein synthesis, disrupting cell function and ultimately leading to cell death. The toxin also incites an inflammatory response, the net effect being to establish a pro-thrombotic state within the microvasculature¹⁵. The concentration of cell surface Gb3 is particularly high in the kidney, not only on the endothelium but also on podocytes and the tubular epithelium. This may explain the susceptibility of the kidney to injury, but other factors, such as high renal blood flow, may also contribute. Gb3 is also found in other tissues, including the central nervous system, that are affected by STEC HUS.

Diagnosis and management. Faecal culture should be performed in all patients with a TMA irrespective of whether there is a history of colitic illness. Diarrhoea may have settled by the time of presentation, but bacteria can still be isolated; therefore, stool or rectal swab should still be sent. PCR can be performed on these samples to detect the presence of Shiga toxin genes.

Positive serology for antibodies against toxin-producing *E. coli* serotypes is supportive of a diagnosis of STEC HUS, although it is not routinely used.

Currently, there is no evidence that treatments other than supportive care, including dialysis and ventilator support as required, improve the outcome of patients with STEC HUS. Plasma-based therapy is no longer recommended for the treatment of STEC HUS and may in fact be harmful¹⁶.

The role of antibiotics is controversial and their use has traditionally been avoided because of concerns that antibiotic treatment leads to more Shiga toxin release, increasing the likelihood and severity of STEC HUS¹⁷. The effect of antibiotics appears to be both antibiotic and *E. coli* strain dependent. The β lactams and trimethoprim/sulfamethoxazole have been reported to increase the risk of developing HUS^{17–19}. Although fluoroquinolones increase toxin production *in vitro*, they do not appear to worsen disease. Some antibiotics, such as macrolides and fosfomycin, reduce toxin synthesis and may reduce the risk of HUS^{20,21}. When antibiotics are required, they can be used, but the choice of antibiotic should be guided by their potential effect on toxin release. In contrast, antibiotic use in patients with HUS due to *Shigella* appears to be safe. Trials of toxin-binding resins have failed to show a benefit.

A role for complement in the pathogenesis, and therefore a rationale for anti-complement therapies, has been proposed. Preclinical studies in rodent models of STEC HUS have suggested that complement activation is involved in disease development^{22–24}; however, animal models of STEC HUS have limitations, and an effect of complement inhibition was not seen in a primate model. In patients with STEC HUS, there is evidence of complement activation²⁵ and C3 levels can be low. In addition, there may be some patients with STEC HUS who also have a defect in complement regulation, and this combination is associated with a poor prognosis^{26–28}. These observations have led to the use of eculizumab, a humanised monoclonal antibody raised against complement protein C5, in patients with STEC HUS. There have been reports of patients with STEC HUS, particularly in the presence of severe disease, responding to eculizumab^{29,30}. However, STEC HUS is a self-limiting disease and therefore these reports have to be interpreted with caution. The use of eculizumab following the outbreak of STEC HUS in central Europe due to *E. coli* O104 yielded conflicting reports, with some suggesting benefit³¹ and others none¹⁶. At present, there is insufficient evidence to support the use of eculizumab in patients with STEC HUS outside of a clinical trial³². Randomised trials in France (ECULISHU, NCT02205541) and the UK (ECUSTEC, ISRCTN 89553116) are investigating the potential benefit of eculizumab in STEC HUS and will provide much-needed evidence in this area.

Pneumococcal HUS

This normally affects children with severe pneumococcal infection, for example pneumonia or empyema, when it complicates approximately 0.5% of cases³³. The exact mechanism of TMA is unknown, but the production of neuraminidase by

Pneumococci appears to be important, although other mechanisms have been proposed³⁴. Neuraminidase strips sialic acid from cell surface glycoproteins, exposing the cryptic Thomsen-Friedenreich (T) antigen, which is recognised by naturally occurring IgM antibodies³⁵. This leads to the activation of platelets and endothelium, which may be responsible for the TMA and also explains why these patients have a positive Coombs (DAT) test.

Pneumococcal pneumonia is the most common preceding infection, but TMA can develop in association with meningitis, empyema, sinusitis, and otitis media. Because of the underlying disease, children are often unwell, with 75% requiring dialysis, and extra-renal manifestations occur frequently³⁶. The mortality rate is higher than with STEC HUS. Treatment is supportive. The role of plasma exchange is uncertain³⁷, and, although a response to eculizumab has been reported^{38,39}, evidence for its use is limited.

HUS occurring in association with other infections

A TMA was a relatively common complication of HIV infection (incidence 2–7%)⁴⁰ but is seen less frequently following the introduction of highly active anti-retroviral therapy (HAART) (<1%)⁴¹. TMA was associated with high viral load, low CD4 count, and opportunistic infection⁴¹ and may be due to a direct effect of the virus on the renal endothelium. Although there have been reports of a response to eculizumab, this is started in combination with HAART and it is therefore difficult to determine which intervention is having the major effect⁴². TMA has been associated with a range of other infections (Table 1), although for most whether they are a direct cause or a trigger for the TMA remains uncertain.

Atypical HUS

Complement-mediated atypical HUS

In the 1990s, excessive activation of complement was identified as a cause of atypical HUS⁴³. An inherited or acquired defect in the control of complement activation can now be found in approximately 60% of cases. In addition, a role for complement activation has been suggested when a TMA occurs in specific clinical scenarios, although the contribution of complement activation in these situations is less clear. In this review, we will consider atypical HUS occurring in the presence of a defined defect in complement regulation as a distinct entity and consider “secondary” TMAs separately.

Clinical features. Complement-mediated atypical HUS predominantly affects the kidney, but, as with other forms of HUS, extra-renal manifestations are also seen in approximately 20% of cases, neurological disease being the most common. Older reports suggest a poor prognosis, with up to 50–60% of patients dying or progressing to ESRD within 1 year of presentation. This is influenced by underlying genetic factors, as patients carrying mutations in complement Factor H have a worse prognosis and those with mutations in CD46 have a milder disease.

Pathogenesis. The complement system is a complex network of over 40 proteins that constitutes a major part of the innate

Table 1. Infections associated with the development of a thrombotic microangiopathy.

Shiga toxin-associated diarrhoeal illnesses
<i>Escherichia coli</i> O157:H7, O26, O80, O91, O103, O104, O111, O121, O145
<i>Shigella dysenteriae</i> type 1
Non-Shiga toxin-associated diarrhoeal illnesses
Norovirus
<i>Clostridium difficile</i>
<i>Campylobacter upsaliensis</i>
Respiratory tract infections
<i>Streptococcus pneumoniae</i>
<i>Haemophilus influenzae</i>
<i>Bordetella pertussis</i>
Other bacterial infections
<i>Fusobacterium necrophorum</i>
Viral infections
HIV
Cytomegalovirus
Epstein Barr virus
Varicella zoster
Influenza
Hepatitis A
Hepatitis C
Coxsackie B
Dengue virus
Human herpes virus 6
Parvovirus B19
Parasitic infections
<i>Plasmodium falciparum</i>

immune system and contributes to the control of the adaptive immune response. Complement is activated through three distinct pathways (Figure 1). The classical pathway is initiated when C1q binds immunoglobulin (IgG and IgM) or other non-immunoglobulin moieties. The lectin pathway is activated when pathogen-associated carbohydrates are recognised by mannose-binding lectin, ficolins, or collectins. The alternative pathway exists in a continuous state of low-level activation in order to respond rapidly to infection but also has an important role in the amplification of the classical and lectin pathways. All pathways converge with proteolytic cleavage of C3, producing C3a and C3b and initiating the terminal complement pathway. This leads to the generation of C5a and assembly of the membrane attack complex, C5b-9, two of the main effectors of complement function. The potential for complement amplification means that tight control is essential to prevent excessive activation, and this is provided by a series of soluble and membrane-bound inhibitors.

Complement Factor H (CFH) is a fluid-phase complement inhibitor with both decay-accelerating and cofactor activity. Inherited defects in Factor H function were the first complement

abnormalities associated with atypical HUS⁴³. The gene for *CFH* exists in a gene cluster (Regulators of Complement Activation cluster) along with five highly homologous genes encoding the Factor H-related proteins (*CFHR1–5*). It is now known that mutations, deletions, and genomic rearrangements are common in this region and variants in *CFH* are the most common disease-causing variants (20–30%)^{44–46}. Mutations in the serine protease Factor I (5–10% of cases)^{47,48} and Membrane Cofactor Protein (MCP, CD46, 10% of cases)^{49,50} are also associated with disease. In addition, an acquired defect in complement control due to autoantibodies against Factor H, usually associated with homozygotic deletion of *CFHR1–3*, can also cause atypical HUS^{51,52}, as can gain-of-function mutations in proteins involved in the activation of complement, including variants in C3 (5% of cases)⁵³ and rarely Factor B⁵⁴. Distinguishing disease-causing mutations from variants of uncertain significance or benign polymorphisms is complex and requires the combination of expert knowledge and application of international standards⁵⁵. Not all patients who carry a mutation develop disease, perhaps 50–60%, with commonly occurring genetic polymorphisms in *CFH* and *CD46*⁵⁶ modifying this risk and an environmental trigger required to precipitate disease.

Figure 1. Activation of the complement cascade. DAF, decay accelerating factor.

Diagnosis and management. Diagnosis is primarily clinical and based on the exclusion of other possible causes of TMA, particularly TTP and STEC infection. C3 can be low in this patient group, but a normal C3 level does not exclude complement-mediated atypical HUS. Genetic screening, assessment for the presence of autoantibodies, and neutrophil surface CD46 levels should be performed in all patients. However, these results, particularly genetic analysis, are not immediately available and therefore do not guide initial diagnosis and early treatment choices.

Plasma exchange was the standard treatment and is still first line until TTP has been excluded (preserved ADAMTS13 activity). Once TTP has been excluded, eculizumab is currently the optimal treatment, but because of its high price this is not available in all countries and plasma exchange is still used. Eculizumab is a highly effective treatment for complement-mediated atypical HUS, establishing remission in >85% of cases⁵⁷ with a significant improvement in renal outcomes⁵⁸. The current licence for eculizumab recommends continued treatment because of the risk of relapse. However, several series have now reported withdrawal of eculizumab in patients with complement-mediated disease, with the risk of relapse particularly low in those patients without a mutation^{59–61}. There is a risk of relapse, particularly in patients with Factor H mutations, but re-introduction of eculizumab rapidly re-establishes remission. The use of complement inhibition to induce remission and intermittently treat relapse may be a future strategy to manage disease that would reduce the treatment burden, cost, and infection risk associated with continuous treatment. As the liver is the main site of complement protein synthesis (with the exception of CD46), liver transplantation has been proposed

as a cure for genetic causes of complement-mediated atypical HUS, particularly in those patients who also require a kidney transplant⁶². With the availability of eculizumab, this option is used less frequently.

For patients with complement-mediated atypical HUS who develop ESRD, there is high risk (80–90%) of recurrent disease following transplantation^{63,64}. This is true for all genetic and acquired causes of aHUS with the exception of patients who have a mutation in *CD46*, which, because it is expressed on the renal transplant endothelium, has normal function in the transplant kidney. Disease can recur in patients in whom no defect in complement regulation is found, although the risk is lower (30%)⁶⁵. Recurrence usually occurs early (within 3–6 months) and is associated with a high risk of graft loss⁶⁴. With the availability of eculizumab, patients can now be successfully transplanted, with options to use eculizumab to treat disease recurrence or prophylactically to prevent recurrence⁶⁶.

Other inherited disorders associated with atypical HUS

Homozygous or compound heterozygous mutations in diacylglycerol kinase ϵ can lead to atypical HUS⁶⁷. The mechanism by which this lipid kinase leads to a TMA is unknown, but a number of possible mechanisms have been suggested, including release of pro-thrombotic factors, platelet activation, and changes in vascular tone. Patients usually present in childhood, significant proteinuria is common, there may be histological features of membranoproliferative glomerulonephritis⁶⁸, and the disease may follow a relapsing–remitting course⁶⁹. Patients commonly progress to CKD and ESRD, at which stage transplant is an option, as disease recurrence has not been reported⁶⁹. There is no effective treatment and, as complement is not

involved in disease development⁷⁰, eculizumab does not control disease^{67,69}.

Methylmalonic aciduria and homocystinuria type C protein is involved in the metabolism of vitamin B12 (cobalamin). Homozygotic or compound heterozygotic mutations in the gene encoding this protein, *MMACHC* (cobalamin C [cblC] defect), causes an atypical HUS-like disease⁷¹ in addition to a wide range of other clinical features including neurological, cardiac, and pulmonary abnormalities (particularly pulmonary hypertension)⁷². Biochemically, patients have elevated plasma homocysteine, low methionine, and methylmalonic aciduria. Biochemical and genetic analysis is vital in patients presenting with a TMA, particularly if there are other clinical abnormalities. Patients usually present in childhood, and without treatment the prognosis is poor, with a 100% mortality reported without treatment⁷². Patients respond to treatment with hydroxocobalamin (B12) and betaine, and treatment can be initiated before the results of biochemical and genetic analyses are available⁷³. Complement is unlikely to have a role in this disease, and experience suggests that eculizumab is ineffective⁷⁴.

Genetic variants in thrombomodulin (*THBD*) have been reported in patients with atypical HUS⁷⁵. Thrombomodulin is part of the coagulation pathway and enhances thrombus formation. It may also activate complement and possibly links these two pathways. New genes associated with atypical HUS are being identified, for example *INF2*⁷⁶, which may provide insights into the pathophysiology of TMA as well as explain the disease in some patients in whom no complement defect is identified.

Atypical HUS occurring in specific clinical scenarios

A TMA can develop in a range of different scenarios and, whilst in some cases, as in pregnancy-associated TMA, patients may have a defect in complement regulation, in most cases no abnormality will be found⁷⁷.

Pregnancy-associated TMA

There are a number of causes of a TMA either during pregnancy or in the post-partum period, including pre-eclampsia, HELLP syndrome, TTP, and atypical HUS. Differentiating among these can be difficult and is reviewed elsewhere⁷⁸. Approximately 20% of cases of atypical HUS occur in association with pregnancy, and these most commonly occur in the post-partum period⁷⁹. A significant proportion of women developing atypical HUS in association with pregnancy have a genetic defect in a complement regulator, suggesting pregnancy is the trigger for disease in women with a genetic predisposition^{79,80}. These observations have led to the use of eculizumab in pregnancy-associated HUS with reports of good outcomes⁸¹, although no trial data are available.

TMA associated with severe hypertension

Severe hypertension causing a TMA and atypical HUS due to an inherited defect in complement regulation can present with identical clinical features. Pre-existing hypertension, particularly if poorly controlled, and other features of hypertensive end organ damage make a secondary TMA more likely. However, if there is no improvement in laboratory parameters

with control of blood pressure, treatment with eculizumab should be considered at least until genetic analysis is available. This strategy avoids missing patients with a defect in complement regulation rather than suggesting that hypertension-mediated TMA will respond to complement inhibition⁸².

Drug-related TMA

The development of a TMA has been reported in association with the use of a range of drugs including those used in the treatment of cancer⁸³, immunomodulators, and anti-platelet drugs (Table 2). For some drugs, this appears to be a direct effect

Table 2. Drugs implicated in the development of a thrombotic microangiopathy.

Chemotherapy drugs
Cisplatin
Mitomycin
Gemcitabine
Vincristine
Oxaliplatin
Pentostatin
Anti-platelet drugs
Clopidogrel
Ticlopidine
Vascular endothelial growth factor inhibitors
Bevacizumab
Ramucirumab
Aflibercept
Immunosuppressive drugs
Ciclosporin
Tacrolimus
Sirolimus
Everolimus
Alemtuzumab (Campath)
Muromonab-CD3
Interferons
Interferon- α
Interferon- β
Tyrosine kinase inhibitors
Sunitinib
Sorafenib
Cediranib
Antibiotics
Penicillin
Ciprofloxacin
Sulfisoxazole
Illicit drugs
Cocaine
Heroin
Ecstasy
Miscellaneous drugs
Oral contraceptive pill
Quetiapine

on the endothelium, as is the case for interferon- β ⁸⁴ and bevacizumab⁸⁵, whilst in the case of quinine the TMA is due to the development of autoantibodies against platelet glycoproteins. The TMA induced by clopidogrel⁸⁶ and ticlopidine⁸⁷ leads to the production of antibodies against ADAMTS13 and a TTP-like disease that responds to plasma exchange. In most cases, the exact mechanism of TMA development is unknown and management is supportive with withdrawal of the causative drug.

Malignancy-related TMA

TMA can occur in a wide range of malignancies including stomach, breast, and bowel cancer and haematological malignancy⁸⁸. The exact mechanism of disease is unknown, but microvascular metastases may initiate the TMA. In some patients, it may be difficult to differentiate between a TMA caused by the malignancy or due to the chemotherapy used in its treatment.

Post bone marrow transplant TMA

The development of a TMA has been reported in 10–40% of patients following allogeneic bone marrow transplantation. There are several factors that could contribute to this, including the graft-versus-host response, calcineurin inhibitors, chemotherapy, and infection. Defects in complement regulation have also been reported⁸⁹, and there is evidence for complement activation (increased soluble C5b-9) in some cases. These observations have led to the use of eculizumab in this situation^{90,91}, although evidence that this should be part of the management of this condition is still lacking.

TMA following solid organ transplantation

A TMA can occur after any solid organ transplant, most frequently kidney transplantation, and is due to a number of factors including calcineurin inhibitor toxicity, ischaemia reperfusion injury, antibody-mediated rejection, and infection. Complement mutations have been reported, in up to 30% from one series⁹², possibly due to recurrence of previously undiagnosed atypical HUS. Complement inhibition should be considered, particularly if there is uncertainty about primary diagnosis or the TMA does not resolve with measures such as calcineurin inhibitor withdrawal.

TMA occurring in patients with autoimmune disease

The presence of a TMA has been reported in association with a range of primary glomerular diseases, for example, IgA nephropathy, ANCA-associated vasculitis, and FSGS. Patients with C3 glomerulopathy, a disease also characterised by complement dysregulation, may also develop a TMA⁹³. A TMA can also develop in lupus nephritis and in patients with antiphospholipid syndrome (APS), particularly catastrophic APS. Complement is activated in both of these diseases and a role for eculizumab has been reported⁹⁴, but evidence from clinical trials is not available. A TMA can also be seen in patients with scleroderma renal crisis.

Concluding remarks

HUS can develop in response to a number of different triggers and in a variety of clinical situations. Identifying the cause of HUS can be difficult but is critical, as the treatment and prognosis is dependent on accurate and timely diagnosis.

References

1. Bitzan M, Zieg J: **Influenza-associated thrombotic microangiopathies.** *Pediatr Nephrol.* 2018; **33**(11): 2009–2025.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Tarr PI, Gordon CA, Chandler WL: **Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome.** *Lancet.* 2005; **365**(9464): 1073–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Jenkins C, Chart H, Smith HR, *et al.*: **Antibody response of patients infected with verocytotoxin-producing *Escherichia coli* to protein antigens encoded on the LEE locus.** *J Med Microbiol.* 2000; **49**(1): 97–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Bruyand M, Mariani-Kurkdjian P, Le Hello S, *et al.*: **Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing *Escherichia coli*, an overview of 10 years of surveillance in France, 2007 to 2016.** *Euro Surveill.* 2019; **24**(8): 1800068.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
5. Pifer R, Sperandio V: **The Interplay between the Microbiota and Enterohemorrhagic *Escherichia coli*.** *Microbiol Spectr.* 2014; **2**(5).
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Karmali MA: **Host and pathogen determinants of verocytotoxin-producing *Escherichia coli*-associated hemolytic uremic syndrome.** *Kidney Int Suppl.* 2009; **75**(Supplement 112): S4–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Brandt JR, Fouser LS, Watkins SL, *et al.*: ***Escherichia coli* O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers.** *J Pediatr.* 1994; **125**(4): 519–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Hahn JS, Havens PL, Higgins JJ, *et al.*: **Neurological complications of hemolytic-uremic syndrome.** *J Child Neurol.* 1989; **4**(2): 108–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Sheth KJ, Swick HM, Haworth N: **Neurological involvement in hemolytic-uremic syndrome.** *Ann Neurol.* 1986; **19**(1): 90–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Majowicz SE, Scallan E, Jones-Bitton A, *et al.*: **Global incidence of human Shiga toxin-producing *Escherichia coli* infections and deaths: a systematic review and knowledge synthesis.** *Foodborne Pathog Dis.* 2014; **11**(6): 447–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Butler T: **Haemolytic uraemic syndrome during shigellosis.** *Trans R Soc Trop Med Hyg.* 2012; **106**(7): 395–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Spinale JM, Ruebner RL, Copelovitch L, *et al.*: **Long-term outcomes of Shiga toxin hemolytic uremic syndrome.** *Pediatr Nephrol.* 2013; **28**(11): 2097–105.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Garg AX, Suri RS, Barrowman N, *et al.*: **Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.** *JAMA.* 2003; **290**(10): 1360–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Sandvig K, Bergan J, Dyve AB, *et al.*: **Endocytosis and retrograde transport of Shiga toxin.** *Toxicol.* 2010; **56**(7): 1181–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Obrig TG: ***Escherichia coli* Shiga Toxin Mechanisms of Action in Renal Disease.** *Toxins (Basel).* 2010; **2**(12): 2769–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Menne J, Nitschke M, Stingle R, *et al.*: **Validation of treatment strategies for enterohaemorrhagic *Escherichia coli* O104:H4 induced haemolytic uraemic syndrome: case-control study.** *BMJ.* 2012; **345**: e4565.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
17. Wong CS, Mooney JC, Brandt JR, *et al.*: **Risk factors for the hemolytic**

- uremic syndrome in children infected with *Escherichia coli* O157:H7: a multivariable analysis. *Clin Infect Dis*. 2012; 55(1): 33–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. Launders N, Byrne L, Jenkins C, *et al.*: Disease severity of Shiga toxin-producing *E. coli* O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009–2012. *BMJ Open*. 2016; 6(1): e009933.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Wong CS, Jelacic S, Habeeb RL, *et al.*: The risk of the hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 infections. *N Engl J Med*. 2000; 342(26): 1930–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. **F** Kakoullis L, Papachristodoulou E, Chra P, *et al.*: Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. *J Infect*. 2019; 79(2): 75–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 21. **F** Safdar N, Said A, Gangnon RE, *et al.*: Risk of hemolytic uraemic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 enteritis: a meta-analysis. *JAMA*. 2002; 288(8): 996–1001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 22. Morigi M, Galbusera M, Gastoldi S, *et al.*: Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. *J Immunol*. 2011; 187(1): 172–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Arvidsson I, Rebetz J, Loos S, *et al.*: Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic *Escherichia coli*-Infected Mice. *J Immunol*. 2016; 197(4): 1276–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Ozaki M, Kang Y, Tan YS, *et al.*: Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. *Kidney Int*. 2016; 90(4): 774–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Thurman JM, Mariani R, Emlen W, *et al.*: Alternative pathway of complement in children with diarrhea-associated hemolytic uraemic syndrome. *Clin J Am Soc Nephrol*. 2009; 4(12): 1920–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Downen F, Wood K, Brown AL, *et al.*: Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. *Clinical Kidney J*. 2017; 10(4): 490–493.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Alberti M, Valoti E, Piras R, *et al.*: Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. *Am J Transplant*. 2013; 13(8): 2201–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, *et al.*: Complement Gene Variants and Shiga Toxin-Producing *Escherichia coli*-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. *Clin J Am Soc Nephrol*. 2019; 14(3): 364–377.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Lapeyraque AL, Malina M, Frémeaux-Bacchi V, *et al.*: Eculizumab in severe Shiga-toxin-associated HUS. *N Engl J Med*. 2011; 364(26): 2561–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Pape L, Hartmann H, Bange FC, *et al.*: Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. *Medicine (Baltimore)*. 2015; 94(24): e1000.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Delmas Y, Vendrely B, Clouzeau B, *et al.*: Outbreak of *Escherichia coli* O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. *Nephrol Dial Transplant*. 2014; 29(3): 565–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. **F** Keenswijk W, Raes A, Vande Walle J: Is eculizumab efficacious in Shiga toxin-associated hemolytic uraemic syndrome? A narrative review of current evidence. *Eur J Pediatr*. 2018; 177(3): 311–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. Spinale JM, Ruebner RL, Kaplan BS, *et al.*: Update on *Streptococcus pneumoniae* associated hemolytic uraemic syndrome. *Curr Opin Pediatr*. 2013; 25(2): 203–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Meinel C, Spatà G, Dahse HM, *et al.*: *Streptococcus pneumoniae* From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. *J Infect Dis*. 2018; 217(3): 358–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Coats MT, Murphy T, Paton JC, *et al.*: Exposure of Thomsen-Friedenreich antigen in *Streptococcus pneumoniae* infection is dependent on pneumococcal neuraminidase A. *Microb Pathog*. 2011; 50(6): 343–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Banerjee R, Hersh AL, Newland J, *et al.*: *Streptococcus pneumoniae*-associated hemolytic uraemic syndrome among children in North America. *Pediatr Infect Dis J*. 2011; 30(9): 736–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. **F** Schwartz J, Padmanabhan A, Aquil N, *et al.*: Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. *J Clin Apher*. 2016; 31(3): 149–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 38. Gilbert RD, Nagra A, Haq MR: Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to *Streptococcus pneumoniae*? *Med Hypotheses*. 2013; 81(3): 400–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Brocklebank V, Kavanagh D: Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. *Clin Kidney J*. 2017; 10(5): 600–624.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Gadallah MF, el-Shahawy MA, Campese VM, *et al.*: Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. *Am J Nephrol*. 1996; 16(5): 446–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Becker S, Fusco G, Fusco J, *et al.*: HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. *Clin Infect Dis*. 2004; 39 Suppl 5: S267–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Freist M, Garrouste C, Szlavik N, *et al.*: Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uraemic syndrome: A case report. *Medicine (Baltimore)*. 2017; 96(51): e9358.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Warwicker P, Goodship TH, Donne RL, *et al.*: Genetic studies into inherited and sporadic hemolytic uraemic syndrome. *Kidney Int*. 1998; 53(4): 836–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Challis RC, Araujo GS, Wong EK, *et al.*: A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. *J Am Soc Nephrol*. 2016; 27(6): 1617–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Goodship TH: Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. *Kidney Int*. 2006; 70(1): 12–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Richards A, Buddles MR, Donne RL, *et al.*: Factor H mutations in hemolytic uraemic syndrome cluster in exons 18–20, a domain important for host cell recognition. *Am J Hum Genet*. 2001; 68(2): 485–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Kavanagh D, Kemp EJ, Mayland E, *et al.*: Mutations in complement factor I predispose to development of atypical hemolytic uraemic syndrome. *J Am Soc Nephrol*. 2005; 16(7): 2150–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Frémeaux-Bacchi V, Dragon-Durey MA, Blouin J, *et al.*: Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. *J Med Genet*. 2004; 41(6): e84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Frémeaux-Bacchi V, Kemp EJ, Goodship JA, *et al.*: The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. *J Med Genet*. 2005; 42(11): 852–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Richards A, Kemp EJ, Liszewski MK, *et al.*: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uraemic syndrome. *Proc Natl Acad Sci U S A*. 2003; 100(22): 12966–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Dragon-Durey MA, Sethi SK, Bagga A, *et al.*: Clinical features of anti-factor H autoantibody-associated hemolytic uraemic syndrome. *J Am Soc Nephrol*. 2010; 21(12): 2180–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Moore I, Strain L, Pappworth I, *et al.*: Association of factor H autoantibodies with deletions of *CFHR1*, *CFHR3*, *CFHR4*, and with mutations in *CFH*, *CFI*, *CD46*, and *C3* in patients with atypical hemolytic uraemic syndrome. *Blood*. 2010; 115(2): 379–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Frémeaux-Bacchi V, Miller EC, Liszewski MK, *et al.*: Mutations in complement C3 predispose to development of atypical hemolytic uraemic syndrome. *Blood*. 2008; 112(13): 4948–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. **F** Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, *et al.*: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uraemic syndrome. *Proc Natl Acad Sci U S A*. 2007; 104(1): 240–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 55. **F** Richards S, Aziz N, Bale S, *et al.*: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015; 17(5): 405–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 56. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, *et al.*: Predisposition to atypical hemolytic uraemic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. *Hum Mol Genet*. 2005; 14(5): 703–12.
[PubMed Abstract](#) | [Publisher Full Text](#)

57. **F** Legendre CM, Licht C, Muus P, *et al.*: **Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.** *N Engl J Med.* 2013; 368(23): 2169–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. Licht C, Greenbaum LA, Muus P, *et al.*: **Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.** *Kidney Int.* 2015; 87(5): 1061–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. **F** Fakhouri F, Fila M, Provôt F, *et al.*: **Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.** *Clin J Am Soc Nephrol.* 2017; 12(1): 50–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. **F** Wijnnsma KL, Duineveld C, Volokhina EB, *et al.*: **Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.** *Nephrol Dial Transplant.* 2018; 33(4): 633–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
61. **F** Ardissino G, Testa S, Possenti I, *et al.*: **Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.** *Am J Kidney Dis.* 2014; 63(4): 633–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
62. Saland JM, Shneider BL, Bromberg JS, *et al.*: **Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.** *Clin J Am Soc Nephrol.* 2009; 4(1): 201–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. **F** Bresin E, Daina E, Noris M, *et al.*: **Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.** *Clin J Am Soc Nephrol.* 2006; 1(1): 88–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Noris M, Remuzzi G: **Thrombotic microangiopathy after kidney transplantation.** *Am J Transplant.* 2010; 10(7): 1517–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. **F** Le Quintrec M, Zuber J, Moulin B, *et al.*: **Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.** *Am J Transplant.* 2013; 13(3): 663–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
66. **F** Zuber J, Fakhouri F, Roumenina LT, *et al.*: **Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.** *Nat Rev Nephrol.* 2012; 8(11): 643–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
67. **F** Lemaire M, Frémeaux-Bacchi V, Schaefer F, *et al.*: **Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.** *Nat Genet.* 2013; 45(5): 531–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
68. **F** Ozaltin F, Li B, Rauhauser A, *et al.*: **DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN.** *J Am Soc Nephrol.* 2013; 24(3): 377–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
69. **F** Azukaitis K, Simkova E, Majid MA, *et al.*: **The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ϵ .** *J Am Soc Nephrol.* 2017; 28(10): 3066–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. **F** Bruneau S, Néel M, Roumenina LT, *et al.*: **Loss of DGK ϵ induces endothelial cell activation and death independently of complement activation.** *Blood.* 2015; 125(6): 1038–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. Baumgartner ER, Wick H, Linnell JC, *et al.*: **Congenital defect in intracellular cobalamin metabolism resulting in homocystinuria and methylmalonic aciduria. II. Biochemical investigations.** *Helv Paediatr Acta.* 1979; 34(5): 483–96.
[PubMed Abstract](#)
72. **F** Beck BB, van Spronsen F, Diepstra A, *et al.*: **Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.** *Pediatr Nephrol.* 2017; 32(5): 733–741.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
73. Carrillo-Carrasco N, Chandler RJ, Venditti CP: **Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.** *J Inher Metab Dis.* 2012; 35(1): 91–102.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Cornec-Le Gall E, Delmas Y, De Parscau L, *et al.*: **Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency.** *Am J Kidney Dis.* 2014; 63(1): 119–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. **F** Delvaeye M, Noris M, De Vriese A, *et al.*: **Thrombomodulin mutations in atypical hemolytic-uremic syndrome.** *N Engl J Med.* 2009; 361(4): 345–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
76. **F** Challis RC, Ring T, Xu Y, *et al.*: **Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.** *J Am Soc Nephrol.* 2017; 28(4): 1084–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
77. **F** Le Clech A, Simon-Tillaux N, Provôt F, *et al.*: **Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.** *Kidney Int.* 2019; 95(6): 1443–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. **F** Gupta M, Feinberg BB, Burwick RM: **Thrombotic microangiopathies of pregnancy: Differential diagnosis.** *Pregnancy Hypertens.* 2018; 12: 29–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
79. **F** Bruel A, Kavanagh D, Noris M, *et al.*: **Hemolytic Uremic Syndrome in Pregnancy and Postpartum.** *Clin J Am Soc Nephrol.* 2017; 12(8): 1237–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
80. **F** Fakhouri F, Roumenina L, Provôt F, *et al.*: **Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.** *J Am Soc Nephrol.* 2010; 21(5): 859–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
81. Ardissino G, Wally Ossola M, Baffero GM, *et al.*: **Eculizumab for atypical hemolytic uremic syndrome in pregnancy.** *Obstet Gynecol.* 2013; 122(2 Pt 2): 487–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. **F** El Karoui K, Boudhabhay I, Pettiprez F, *et al.*: **Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome.** *Haematologica.* 2019; pii: haematol.2019.216903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
83. Izzedine H, Perazella MA: **Thrombotic microangiopathy, cancer, and cancer drugs.** *Am J Kidney Dis.* 2015; 66(5): 857–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
84. **F** Kavanagh D, McGlasson S, Jury A, *et al.*: **Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.** *Blood.* 2016; 128(24): 2824–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. **F** Eremina V, Jefferson JA, Kowalewska J, *et al.*: **VEGF Inhibition and Renal Thrombotic Microangiopathy.** *N Engl J Med.* 2008; 358(11): 1129–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. Zakarija A, Bandarenko N, Pandey DK, *et al.*: **Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.** *Stroke.* 2004; 35(2): 533–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, *et al.*: **Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.** *Ann Intern Med.* 1998; 128(7): 541–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Morton JM, George JN: **Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer.** *J Oncol Pract.* 2016; 12(6): 523–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Jodele S, Licht C, Goebel J, *et al.*: **Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.** *Blood.* 2013; 122(12): 2003–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Jodele S, Fukuda T, Vinks A, *et al.*: **Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.** *Biol Blood Marrow Transplant.* 2014; 20(4): 518–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. de Fontbrune FS, Galambun C, Sirvent A, *et al.*: **Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.** *Transplantation.* 2015; 99(9): 1953–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Le Quintrec M, Lionet A, Kamar N, *et al.*: **Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.** *Am J Transplant.* 2008; 8(8): 1694–701.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. **F** Ankawi GA, Clark WF: **Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?** *BMJ Case Rep.* 2017; 2017: pii: bcr-2017-220974.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
94. Barratt-Due A, Fleisand Y, Orrem HL, *et al.*: **Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.** *Rheumatology (Oxford).* 2016; 55(7): 1337–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Aoife Waters**

University College London, Great Ormond Street Institute of Child Health, London, UK

Competing Interests: No competing interests were disclosed.

2. **Richard Coward**

Bristol Medical School, University of Bristol, Bristol, UK

Competing Interests: No competing interests were disclosed.

3. **Chantal Loirat**

Université de Paris, Hôpital Universitaire Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research